What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly (NYSE:LLY) underwent analysis by 7 analysts ... and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. Market Capitalization: Positioned above industry average, the ...

Eli Lilly has struck a $2.4 billion deal to buy ... like Novartis’ multibillion-dollar blockbuster Cosentyx (secukinumab), Lilly’s Taltz (ixekizumab), Bausch Health/Ortho’s Siliq (brodalumab ...

An injected drug, Cosentyx became a blockbuster last year with sales of $1.1 billion, and Novartis is looking for ways to gain an advantage over Eli Lilly’s rival IL-17A inhibitor, Taltz ...

Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly ( LLY 14.56%). But now, an investment ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows to some extent with companies including Johnson & Johnson, Pfizer ...